# Appendix D: Reference Materials

---

## D.1 Glossary of Terms

### D.1.1 Clinical Assessment Scales

| Term | Full Name | Description |
|------|-----------|-------------|
| **NIHSS** | National Institutes of Health Stroke Scale | NIH stroke scale, 0-42 points, higher = more severe |
| **mRS** | Modified Rankin Scale | Functional outcome scale, 0-6 points, 0-1 = excellent outcome |
| **ASPECTS** | Alberta Stroke Program Early CT Score | Early CT score, 10 = normal, lower = more severe |

### D.1.2 Hemorrhage-Related Terms

| Term | Full Name | Description |
|------|-----------|-------------|
| **sICH** | Symptomatic Intracranial Hemorrhage | Symptomatic brain bleeding with clinical deterioration |
| **aICH** | Asymptomatic Intracranial Hemorrhage | Brain bleeding visible on imaging but no symptoms |
| **INR** | International Normalized Ratio | Coagulation measure, 1.0 = normal |

### D.1.3 Molecular and Drug Terms

| Term | Description | Analogy |
|------|-------------|---------|
| **Plasminogen** | Thrombolytic precursor in blood, **inactive by itself** | Unlit match |
| **Plasmin** | The active thrombolytic enzyme | Lit match |
| **Fibrin** | Main protein forming clot mesh | Glue |
| **tPA** | Tissue-type Plasminogen Activator | Universal solvent |
| **uPA** | Urokinase-type Plasminogen Activator | Specialized solvent |
| **uPAR** | Cell surface receptor for uPA | USB port |
| **PAI-1** | Plasminogen Activator Inhibitor-1, braking system | Car brakes |

### D.1.4 Stroke Types

| Type | English | Description | Thrombolysis Efficacy |
|------|---------|-------------|----------------------|
| **Cardioembolic** | Cardioembolic | Clot from heart | Best |
| **Large Artery Atherosclerosis** | Large Artery Atherosclerosis | Plaque rupture | Fair |
| **Lacunar** | Lacunar | Deep small vessel disease | Almost ineffective |
| **Unknown** | Unknown | No identifiable cause | Uncertain |

### D.1.5 Clinical Trial Terms

| Term | Description |
|------|-------------|
| **Phase 1** | Phase 1 trial, tests safety, 20-100 patients |
| **Phase 2** | Phase 2 trial, tests efficacy + dose, 100-500 patients |
| **Phase 3** | Phase 3 trial, large-scale validation, 1,000+ patients |
| **Upfront** | Signing fee, one-time payment at signing |
| **Milestone** | Milestone payment, paid upon achieving targets |
| **Royalty** | Sales royalty, percentage of post-launch sales |

---

## D.2 Clinical Trial Registry Links

### D.2.1 LT3001 Trials

| Trial ID | Link |
|----------|------|
| LT3001-105 | [ClinicalTrials.gov NCT04809818](https://clinicaltrials.gov/ct2/show/NCT04809818) |
| LT3001-201 | [ClinicalTrials.gov NCT04091945](https://clinicaltrials.gov/ct2/show/NCT04091945) |
| LT3001-202 | [ClinicalTrials.gov NCT05686642](https://clinicaltrials.gov/study/NCT05686642) |
| LT3001-203 | [ClinicalTrials.gov NCT05198323](https://clinicaltrials.gov/study/NCT05198323) |
| LT3001-205 | [ClinicalTrials.gov NCT05403866](https://clinicaltrials.gov/study/NCT05403866) |
| LT3001-103 (China) | [China Drug Trials Registry](http://www.chinadrugtrials.org.cn/) |

### D.2.2 Competitor Trials

| Drug | Trial | Link |
|------|-------|------|
| JX10 | ORION Phase 2/3 | [ClinicalTrials.gov NCT06990867](https://clinicaltrials.gov/study/NCT06990867) |
| DM199 | REMEDY-2 | ClinicalTrials.gov |
| ApTOLL | Phase 3 | ClinicalTrials.gov |

---

## D.3 Academic Literature Citations

### D.3.1 LT3001 Related

| Source | Title | Year |
|--------|-------|------|
| Research Square | *Effects of a new thrombolytic compound LT3001 on acute brain tissue damage after focal embolic stroke in rats* | 2022 |
| Harvard/Tulane University | Animal study paper (Jiang Y, Ji Y, Zhou IY, et al.) | 2022 |

### D.3.2 JX10 Related

| Source | Title | Year |
|--------|-------|------|
| Stroke | *Anti-Inflammatory Thrombolytic JX10 (TMS-007) in Late Presentation of Acute Ischemic Stroke* | 2024 |
| Supplemental Material | Tables S1-S9, Figures S1-S2 | 2024 |

### D.3.3 Stroke Treatment Milestones

| Trial | Year | Finding | Impact |
|-------|------|---------|--------|
| NINDS | 1995 | tPA effective (0-3 hr) | tPA approved |
| ECASS-3 | 2008 | tPA extended to 4.5 hr | Window expansion |
| MR CLEAN et al. | 2015 | EVT effective (0-6 hr) | EVT becomes standard |
| DAWN, DEFUSE-3 | 2018 | EVT extended to 24 hr | Imaging selection era |
| SELECT-2, RESCUE-Japan LIMIT | 2024 | EVT for large core infarcts | Indication expansion |

---

## D.4 Epidemiological Data Sources

| Source | Description |
|--------|-------------|
| **GBD 2021** | Global Burden of Disease Study |
| **WHO** | World Health Organization statistics |
| **AHA/ASA Guidelines** | American Heart/Stroke Association treatment guidelines |
| **Stroke Journal** | Clinical trial publication journal |
| **ClinicalTrials.gov** | U.S. clinical trial registry |

---

## D.5 Market Research Sources

| Source | Description |
|--------|-------------|
| Grand View Research | Market size reports |
| Mordor Intelligence | Competitive landscape analysis |
| Evaluate Pharma | Drug sales forecasts |
| SEC Filings | Public company financial data |

---

## D.6 Official Company Resources

| Resource | Link |
|----------|------|
| Lumosa website | [https://www.lumosa.com.tw/tw](https://www.lumosa.com.tw/tw) |
| Taiwan Exchange (MOPS) | [6535 Lumosa](https://mops.twse.com.tw/) |
| Investor presentations | Company website / MOPS |

---

## D.7 Regulatory Agencies

| Agency | Full Name | Jurisdiction |
|--------|-----------|--------------|
| **FDA** | U.S. Food and Drug Administration | U.S. |
| **NMPA** | National Medical Products Administration | China |
| **EMA** | European Medicines Agency | EU |
| **PMDA** | Pharmaceuticals and Medical Devices Agency | Japan |
| **TFDA** | Taiwan Food and Drug Administration | Taiwan |

---

## D.8 International Advisory Board

| Expert | Title | Significance |
|--------|-------|--------------|
| **Marc Fisher** | President of World Stroke Organization, Professor of Neurology at Harvard Medical School | Highest authority in global stroke field |
| **Yongjun Wang** | Director of Beijing Tiantan Hospital, President of China Stroke Association | LT3001-202 Principal Investigator |
| Gregory Albers | Director of Stanford Stroke Center | Inventor of RAPID imaging technology |
| Pooja Khatri | Director of Cincinnati Acute Stroke Center | Authority on U.S. stroke clinical practice |
| David Liebeskind | Director of UCLA Stroke Center | Neurovascular imaging expert |
| Carlos Molina | Vall d'Hebron Hospital, Barcelona | European stroke center leader |
| Han-Hua Hu | Founding President of Taiwan Stroke Society | Taiwan stroke field authority |

---

## D.9 Abbreviation Reference Table

| Abbreviation | Full Name |
|--------------|-----------|
| AIS | Acute Ischemic Stroke |
| BBB | Blood-Brain Barrier |
| BD | Business Development |
| BLA | Biologics License Application |
| DCF | Discounted Cash Flow |
| EPS | Earnings Per Share |
| EVT | Endovascular Thrombectomy |
| ICA | Internal Carotid Artery |
| ICH | Intracranial Hemorrhage |
| IND | Investigational New Drug (application) |
| KOL | Key Opinion Leader |
| LAA | Large Artery Atherosclerosis |
| LVO | Large Vessel Occlusion |
| MRA | Magnetic Resonance Angiography |
| NDA | New Drug Application |
| P/S | Price-to-Sales ratio |
| ROI | Return on Investment |
| SAE | Serious Adverse Event |
| TOAST | Trial of Org 10172 in Acute Stroke Treatment (stroke classification) |

---

## D.10 Disclaimer

All analysis in this book is based on publicly available information, including:

- Company announcements and investor presentations
- Clinical trial registries and published papers
- Regulatory agency public documents
- Market research reports
- Media coverage

**This book does not constitute investment advice.**

New drug development involves high uncertainty. Even the most optimistic analysis carries possibility of complete failure. Investors should conduct independent research, assess personal risk tolerance, and never invest money they cannot afford to lose.

---

**[Previous Appendix: Appendix C â€” License Value Estimation Model](-Appendix_C_License_Model.md)** | **[Return to Table of Contents](-README.md)**

---

*Last updated: January 2026*
